Skip main navigation

Home > Search Results

Main contents starts here

Search Results

61 - 80 of about 337

Total 337 documents found.

  •  
  • SUMMARY OF FINANCIAL STATEMENTS [Japan GAAP] (CONSOLIDATED) Financial Results for the First Quarter (April 1 to June 30, 2010) of the Fiscal Year Ending March 31, 2011 July 30, 2010 Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President & CEO Contact: Hiroshi Ohtsuki Corporate Officer, Senior Vice President, Corporate Communications Department Telephone: +81-3-3278-2037 Scheduled date of securities report submission: August 10, 2010 Scheduled date of dividend payment commencement: Supplementary materials for the quarterly financial statements: Yes Presentation to explain for the quarterly financial statements: Yes (Millions of yen, rounded to the nearest million) 1. Consolidated Financial Results (April 1 to June 30, 2010) for the Fiscal Year Ending March 31, 2011 (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of t
  • CSR in Takeda
  • Throughout our more than 220-year history, Takeda has maintained a strong commitment to society, demonstrating high ethical standards and living up to our mission of promoting better health for individuals and progress in medicine.
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Two Quarters (April 1 to September 30, 2009) of the Fiscal Year Ending March 31, 2010 October 30, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: November 13, 2009 Scheduled date of dividend payment commencement: December 1,2009 1. Consolidated Financial Results (April 1 to September 30, 2009) of the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( millio
  • 34 Intellectual property activities are vital to our ability to contribute to society as a provider of outstanding pharmaceutical products The Four Central Themes of Intellectual Property Activities Well over 10 years is needed for the R&D process that extends from drug discovery to final approval of a new pharmaceutical product. Furthermore, despite the enormous expenditures required to develop drugs, only a very small percentage of compounds reach the market. Drugs that are approved for sale in most cases are protected by a substance patent, which covers the drug's active ingredient. This patent is critical to the R&D process. Prospects for obtaining a patent can even be the deciding factor in whether or not to proceed with the development of a product. This is why all pharmaceutical companies place so much importance on the effective use of intellectual property, including basic patents. Without sufficient intellectual property, companies would be unable to generate the earnings needed for drug developmen
  • SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Three Quarters (April 1 to December 31, 2009) of the Fiscal Year Ending March 31, 2010 February 3, 2010 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 15, 2010 Scheduled date of dividend payment commencement: 1. Consolidated Financial Results (April 1 to December 31, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( milli
  • 76 Feature Supply Chain Management Fundamental Policy Takeda is accelerating the globalization of its operations to realize its corporate mission of providing superior products worldwide to contribute to the health of as many patients as possible. In proportion to this globalization, our supply chains from procurement of raw materials, to production, distribution and marketing involve more companies and facilities in different countries with increasing complexity. Meanwhile, in recent years counterfeit drugs as well as counterfeit and adulterated raw materials pose a threat to the health of patients and consumers globally. In 2008 alone, there have been nearly 2,000 incidents around the world involving counterfeit pharmaceutical products. Over the past few years, the number of reported cases of counterfeit products has doubled. In 2008, about 500 consignments of counterfeit drugs were blocked for entry at Japanese customs, which has surged five times since 2006. Meanwhile, counterfeit products are becoming i
  • 42 Japanese Market The Wakayama Representative Office (clockwise from left): Yuuichi Ohmoto, Tomotaka Sakurai, Keita Nakajima (Manager), Megumi Tanaka, Nobukazu Takamori, Kazuhiro Hosono, Hirokazu Nakamoto A more powerful platform for global marketing enhancing Takeda's stature in Japan, the U.S., Europe and Asia Takeda positions Japan, its home country, as a primary source of growth for the entire group. However, market conditions in Japan are challenging: to bring down health care expenses, the Japanese government is promoting generic drugs and expanding DPC (Diagnosis Procedure Combination). Within this context, our goal is to retain our leading market position, and we intend to do this by reinforcing our commitment to operating from the perspective of health care professionals and, above all, patients. Japan's No. 1 Drug Company Again in Fiscal 2008 Takeda's ethical drug sales in Japan increased 3.6 percent to 549.0 billion in fiscal 2008. In addition to leadership overall, we ranked first in drug sales
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 20 - 3. Management Policy (1) Basic Management Policy Focusing on "Takeda-ism" (which refers to integrity = fairness, honesty, and perseverance) as the basis for all its business activities, Takeda is aiming at realizing its management mission of "striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products" through creating new drugs continuously and maximizing the product's potential in the global market as a research-based pharmaceutical company. In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company" as targeted in the 20062010 Medium-term Plan, Takeda created corporate-level, center of excellence R&D, commercial and administrative functions in fiscal 2009, and we will build its organization for global operations. Takeda will dedicate its collective efforts to thoroughly enhance its strengths, such as its "capabilit
  • 17 Corporate Governance Policy toward Corporate Governance Fundamental Policy and Structure Based on the Mission: "we strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products," Takeda strives to strengthen internal control, including thorough compliance, as well as promoting the establishment of a system allowing the creation of a healthy and transparent environment for quick decision-making, toward the establishment of a management framework befitting a "worldclass pharmaceutical company." Through these efforts, we will promote efforts to optimize the corporate value, aiming to further enhance our corporate governance. Auditing System The organizational form is a company with auditing officers. Takeda has established a system as the "Audit Rules by Corporate Auditors" with the aim of ensuring audits by auditors are implemented effectively by detailing the activities of auditors, including attending important meetings and authority to browse importan
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company", which was set as a target in the 20062010 Medium-term Plan, the Company has been working on various strategies. To achieve this goal, the Company completed a meaningful acquisition and restructuring last year. Firstly, we evenly separated the value of TAP Pharmaceutical Products Inc. ("TAP")a joint venture between Takeda America Holdings, Inc. ("TAH") and Abbott Laboratories ("Abbott") of the U.S.into two companies in April 2008. As part of this company separation, TAP acquired assets related to the already marketed product Prevacid, as well as those related to TAK-390MR (a drug for gastroesophageal reflux disease) and TMX-67 (a drug for hyperuricemia for patients with chronic gout, discovere
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Nine Months Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 February 3, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 13, 2009 1. Consolidated Financial Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Nine months ended December 31, 2008 1,202,760 239,884 254,578 168,573 Nin
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 10 - (4)Management Policy Basic Management Policy Focusing on "Takeda-ism (which refers to integrity equaling fairness, honesty, and perseverance) as the basis for all its business activities, Takeda is aiming to realize its management mission of "striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products." As part of the five-year 2006-2010 Medium-Term Plan, Takeda has been working towards the "creation of a global pharmaceutical company" with a strong medium-to long-term vision. Takeda aims to achieve this goal by focusing its collective efforts so as to enhance its inherent strengths, such as its "capability to establish and implement in-depth strategies from a long-term perspective" and its "high productivity and efficiency." At the same time, all energies of the Group will be concentrated on the followi
  • 22 Europe R&D in In order to help you further deeply understood Takeda's "current" and "future" globalization, a special feature in terms of our European operations is introduced in this section over six pages. Takeda has responded to industry trends, namely the socalled "integration of the global pharmaceutical market," from an early stage, since advancing to establish structures of R&D and the Japan-U.S.-Europe tripolar marketing functions. In Europe, we have been promoting following various approaches to establish our operating base. In fiscal 2006, we launched Takeda Cambridge Limited (TCB), which is anticipated to play a role in the global R&D network, as well as Takeda Pharmaceuticals Europe Limited (TPEU), which supervises the overall sales activities of Takeda's six subsidiaries in Europe. In addition, we also have been proactively participating in CSR activities, aiming to make further contributions to our stakeholders. Takeda Pharmaceuticals Europe Limited (U.K.) Takeda Cambridge Limited Takeda Glo
  • Chairman Kunio Takeda 4 We have been striving to realize our corporate philosophy: "Takeda-ism," aiming to become a "world-class pharmaceutical company with Japanese origin." President Yasuchika Hasegawa Net sales in fiscal 2006, which was the first year of the 2006-2010 Medium-Term Management Plan, reached 1.3052 trillion (a 7.7 percent increase over the previous year). Net sales of the pharmaceutical business reached 1.2028 trillion (an 11.9 percent increase over the previous year), which resulted in an increase of its ratio to total sales up to 92.2 percent from 88.6 percent in the previous year, achieving to reach over 90 percent for the first time. Net sales of the ethical drug business have also increased to achieve 1.1441 trillion (a 12.3 percent increase over the previous year). Domestic net sales of ethical drugs reached 514.9 billion (a 4.3 percent increase over the previous year). In addition to the significant increase in sales of anti-diabetic drug, Actos (generic name: pioglitazone hydrochlorid
  • FUNDAMENTAL POLICY Based on the Mission: "we strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products," Takeda strives to establish a management framework befitting a "world-class pharmaceutical company with Japanese origin," which operates business worldwide. We, therefore, strengthen internal control, including thorough compliance, as well as promoting the establishment of a system allowing the creation of a healthy and transparent environment for quick decision-making, while clarifying the responsibilities and authority systems of the whole group. AUDITING SYSTEM The organizational form is a company with auditing officers. As for improving the transparency of management by utilizing human resources from outside the company, we consider that the objectivity and impartiality of the management observation function have been successfully secured through audit by three external auditors (out of four auditors in total) and fully functioning. Deloitte To
  • Growth toward a WorldGrowth toward a World--class Pharmaceuticalclass Pharmaceutical Company with Japanese OriginCompany with Japanese Origin YasuchikaYasuchika HasegawaHasegawa President & COOPresident & COO Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited May 11, 2006May 11, 2006 Fiscal 2005 Financial Results andFiscal 2005 Financial Results and Outline ofOutline of ""20062006--2010 Medium2010 Medium--Term Management PlanTerm Management Plan"" AgendaAgenda Fiscal 2005 Financial Results Review of "2001-05 Medium-Term Management Plan" 2006-2010 Medium-Term Management Plan Management tasksManagement tasks 1.1. Enhancement of capability to create new drugsEnhancement of capability to create new drugs through inthrough in--house R&Dhouse R&D activitiesactivities 2. Formulation of2. Formulation of a tria tri--polar marketing functionpolar marketing function 3. Establishment of an efficient3. Establishment of an efficient global management schemeglobal management scheme for corporatefor
  • Growth toward a WorldGrowth toward a World--class Pharmaceuticalclass Pharmaceutical Company with Japanese OriginCompany with Japanese Origin YasuchikaYasuchika HasegawaHasegawa President & COOPresident & COO Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited May 11, 2006May 11, 2006 Fiscal 2005 Financial Results andFiscal 2005 Financial Results and Outline ofOutline of ""20062006--2010 Medium2010 Medium--Term Management PlanTerm Management Plan"" AgendaAgenda Fiscal 2005 Financial Results Review of "2001-05 Medium-Term Management Plan" 2006-2010 Medium-Term Management Plan Management tasksManagement tasks 1.1. Enhancement of capability to create new drugsEnhancement of capability to create new drugs through inthrough in--house R&Dhouse R&D activitiesactivities 2. Formulation of2. Formulation of a tria tri--polar marketing functionpolar marketing function 3. Establishment of an efficient3. Establishment of an efficient global management schemeglobal management scheme for corporatefor
  • Consolidated Financial Statements for the Interim Period of Fiscal 2005 November 4, 2005 These financial statements have been prepared for reference only in accordance with accounting principles and practices generally accepted in Japan. Takeda Pharmaceutical Company Limited Stock exchange listings: Osaka, Tokyo, Nagoya (First Section of each), 1-1, Doshomachi 4-chome Fukuoka, Sapporo Chuo-ku, Osaka 540-8645, Japan Code number: 4502 URL: http://www.takeda.co.jp/ Board of Directors meeting: November 4, 2005 Representative: Yasuchika Hasegawa, President and COO Use of U.S. accounting standards: No Contact: Toyoji Yoshida, Director Telephone: +81-6-6204-2060, +81-3-3278-2039 1. Results for the Interim Period of Fiscal 2005 (April 1, 2005-September 30, 2005) (1) Sales and Income All amounts are rounded to the nearest million yen. Net sales ( million) Year-on-year change (%) Operating income ( million) Year-on-year change (%) Ordinary income ( million) Year-on-year change (%) Interim period of fiscal 2005 Interim
  • 45 Safety and Health of Employees Takeda allocates a Safety and Health Officer for every business unit, where all members participate in activities to ensure safety and health in their workplace. Approach to Accident Prevention Based on the annually prepared "Policies on Accident Prevention," each business unit makes a concrete plan to implement preventive measures against accidents and disasters. The performance and progress of these preventive measures are closely checked by the internal environmental protection and accident prevention audit. Takeda adopts both "hard" and "soft" approaches to accident prevention. The "hard" approach includes intensive control of facilities, including a phased plan for the refurbishment of aging facilities and specific measures against static electricity, flammable substances, etc. In addition, the internal environmental protection and accident prevention audit and the safety diagnosis designed for manufacturing plants are used to identify potential risks and measures are p

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top